Generics BulletinBiocon Biologics has celebrated approval of its Kirsty (insulin aspart-xjhz) 100 units/ml biosimilar rival to Novo Nordisk’s Novolog by the US Food and Drug Administration, indicated to improve glycem
Generics BulletinThe UK Medicines and Healthcare products Regulatory Agency has approved Biocon Biologics’ two denosumab biosimilars. Set to be marketed under the name Vevzuo, referencing Amgen’s Xgeva brand, the bios
Generics BulletinAround 18 months on from integrating the biosimilars business in Europe that it acquired from former partner Viatris, Biocon Biologics is continuing to push forward with a regular cadence of new app
Generics BulletinHealth Canada has greenlit Biocon Biologics’ Yesafili, making it the first biosimilar rival to Regeneron’s Eylea (aflibercept) in the country. Yesafili was approved in vial and pre-filled syringe pres